HOME      CAREERS      CONTACT US    TRIO     
 

Enter the Intranet website !

Home

Welcome to Cancer International Research Group
a division of TRIO (Translational Research in Oncology).

CIRG is a not-for-profit clinical research organization with offices based in Canada, France and Uruguay.
With an international network of 2000 investigators and 450 cancer centers in over 45 different countries, CIRG has conducted a number of new and innovative global studies evaluating systemic therapy for cancer.

Under the merged entity of TRIO, the CIRG division is building a strong collaboration with TORI the wide group of preclinical researchers at UCLA to become part of an exciting innovative translational research program. 

CIRG is developing from proof of concept up to registrational phase  III trials in different setting such as breast, ovary, GI….

_____________________________________

 

> Last News :

  • Information on CCO point-of-care resource designed specifically for oncologists, click here for more information

  • 3rd analysis of BCIRG 006 presented by Dr Slamon on December 12 at the 2009 SABCS conference (GENERAL SESSION 5 -Exhibit Hall D)
    Abstract 62. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC -> T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC -> TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study

    Click here to access the official BCIRG 006 Presentation in pdf format (Slides set in jpg format - zipped file)

  • 2nd analysis of CIRG/TORI 010 study presented at the 2009 SABCS conference by Dr John Mackey from the Cross cancer Institute , abstract 47 CIRG/TORI 010: First Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel (P) as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)

    Click here to access the official CIRG/TORI 010 Presentation

  • Analysis of Fcg Receptor IIa and IIIa Polymorphisms: Correlation with Outcome in Trastuzumab-Treated Her2/neu Amplified Early and Metastatic Breast Cancer Patients (from breast cancer patients treated in the BCIRG-006 study) presented by Dr. Sara Hurvitz from UCLA at 2009 SABCS conference. Abs.64 Click here to access slides presentation

For information on new TRIO-CIRG studies please click in the Studies Summary on left side menu.

________________________________________________________

Copyright 2010 - Translational Research In Oncology